ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
February 26, 2024
Oncology
ImmuneOnco is a HongKong stock exchange-listed, clinical stage biotech company focused on discovering and developing immunotherapies to treat cancer.
The most advanced clinical program is timdarpacept (IMM01), an SIRPα-IgG1 Fc with ADCC/ADCP inducing activity. It is going to enter phase III in 2024 with the planned BLA submission in 2025 to treat higher-risk myelodysplastic syndromes (HR-MDS) and R/R classic Hodgkin lymphoma (cHL). Timdarpacept in combination with azacitidine to treat chronic myelomonocytic leukemia (CMML) was approved by FDA for Orphan Drug Designation.
Other clinical stage assets include VEGFxPD-L1, PD-L1xCD47, CD47xCD20, CD47xHER2 (Fast Track designation by FDA), ADCC-enhanced CTLA-4 mAb, CD24 mAb, CD70 mAb etc.
)
){kind=logo}
)
){kind=logo}
){kind=logo}